HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Active surveillance redefines paradigm for prostate cancer management
• Indoor tanning declines, but more melanoma prevention efforts urgently needed
• The value proposition in oncology: ASCO and ESMO bite the bullet Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Adcetris for high-risk patients with classical Hodgkin's lymphoma
• FDA clears low-dose CT lung cancer screening option
• FDA grants orphan drug designation to inecalcitol for AML
• FDA grants orphan drug designation to varlitinib for cholangiocarcinoma
• FDA grants priority review to Keytruda for first-line treatment of advanced melanoma
• FDA reports prescribing, dispensing errors between Brintellix, Brilinta
• ADAMTS mutations may predict chemotherapy response in ovarian cancer
• AGS-003 plus sunitinib shows promise for advanced renal cell carcinoma
• Annual low-dose CT screening limits unnecessary surgery in patients with nonsolid lung nodules
• ATA releases first guidelines for pediatric thyroid nodules, cancer
• ATRX mutation possible biomarker for rare neuroendocrine tumors
• Black men in the UK twice as likely to receive prostate cancer diagnosis
• CA-IX predicts poor survival in resectable hepatocellular carcinoma
• Colorectal cancer more survivable when detected by screening vs. diagnostic colonoscopy
• Concomitant antidepressant, NSAID use may raise risk for intracranial hemorrhage
• Diagnostic model predicts impending death in patients with cancer
• Donepezil displays some cognitive benefit for patients with irradiated brain tumors
• Doxorubicin can be omitted from postoperative Wilms’ tumor treatment
• Earlier palliative care consultation may reduce hospital cost, length of stay
• Elevated C-reactive protein predicts poorer outcomes in melanoma
• Esophageal cancer rates in men increase by nearly 50% in 30 years
• Fluorescent molecular imaging helps identify lung adenocarcinomas
• Gene expression profiling, SLNB improved prediction of metastasis risk in patients with melanoma
• Genomic alterations predict chemotherapy response in muscle-invasive bladder cancer
• Graft-versus-host disease causes enteric bacterial BSI in children after HCT
• High TIL levels predict positive outcomes in HER-2–positive breast cancer
• Hypofractionated radiation, temozolomide effective in elderly patients with glioblastoma
• Low-dose olprinone reduces risk for atrial fibrillation after lung cancer surgery
• Lower intensity treatment regimen displays efficacy in older patients with AML
• Model predicts hearing loss after chemoradiotherapy for head and neck cancer
• MRD positivity prognostic of poor outcomes even after intensive therapy for B-ALL
• MRI-based screening effective for pancreatic cancer detection
• Nearly 15 million women have no access to GYN oncology care
• No link between statin use, increased OS in colorectal cancer
• Patient confidence in trial participation unaffected by knowledge of placebo assignment
• Physicians working sick despite health risk to patients
• Radiotherapy has modest impact on quality of life when added to ADT
• Researchers successfully transport blood samples via drones
• Single dose of bivalent HPV vaccine as effective as three
• Society establishes criteria, research goals for oncology nurse navigators
• Society of Gynecologic Oncology outlines recommendations for ovarian cancer prevention
• Study data show increase in use of Mohs' micrographic surgery for skin cancer treatment
• Testosterone therapy not linked to VTE
• Treatment delays, missed diagnostic testing common among patients with lung cancer
• Treatment-related cardiac dysfunction common in adult survivors of childhood cancer
• Workers exposed to low-dose radiation face increased leukemia mortality risk
• ASH presents bridge grants to 13 investigators
• ASTRO members receive fellows designation
• MD Anderson appoints orthopedic oncology department chair
• NYU Langone appoints neuro-oncology chief
• Vanderbilt appoints radiation oncology chair
• Effective methods exist to prevent, treat therapy-related dermatologic adverse events Jai N. Patel, PharmD, BCOP, CPP